SequelSEC

TuHURA Biosciences, Inc./NV HURA

Pharmaceutical Preparations · CIK 0001498382 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2026-03-31
Operating income
Unavailable
Fiscal year ended 2026-03-31
Free cash flow
-$4.46M
Fiscal year ended 2026-03-31

TuHURA Biosciences, Inc./NV (HURA) reported revenue of $0 and net income of -$7.54M for the fiscal year ended 2026-03-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from TuHURA Biosciences, Inc./NV’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

TuHURA Biosciences, Inc./NV income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-31
Revenue$0$0$0$0$0$0$0$0$0Unavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net income-$7.54M-$6.76M-$7.10M-$9.52M-$6.66M-$6.00M-$5.58M-$5.27M-$4.84M-$1.02M
Research & development$5.23M$6.06M$4.97M$4.93M$4.58M$3.98M$2.95M$2.82M$3.59M$111.00K
Weighted-average diluted sharesshares 60.01MUnavailableshares 50.67Mshares 44.56Mshares 43.40MUnavailableshares 12.18Mshares 12.18Mshares 12.17MUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-0.13Unavailable$-0.14$-0.21$-0.15Unavailable$-0.54$-0.43$-0.40Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$2.30M-$1.56M$1.76M$1.86M$2.02M$1.28M$783.46K$795.66K$1.02M$908.00K
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

TuHURA Biosciences, Inc./NV balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-31
Cash & equivalents$6.30M$3.62M$2.70M$8.51M$6.22M$12.66M$3.02M$4.91M$6.35M$3.67M
Total assets$29.70M$27.35M$25.70M$34.62M$14.64M$19.97M$4.14M$6.20M$7.45M$4.36M
Current assets$6.98M$4.62M$3.50M$12.54M$14.33M$19.61M$3.48M$5.53M$6.76M$4.16M
Total liabilities$6.51M$6.42M$8.92M$15.17M$4.78M$5.37M$2.44M$2.44M$1.52M$5.92M
Current liabilities$6.07M$5.92M$8.83M$15.17M$4.78M$5.33M$2.26M$2.26M$1.34M$3.60M
Total equity incl. NCI$23.19M$20.93M$16.78M$19.45M$9.86M$14.59M-$2.77M-$6.96M-$6.07M-$1.56M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Goodwill$10.74M$10.74M$13.55M$13.55MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$3.95M$3.77M$4.13M$3.65M$3.08M$3.15M$1.87M$1.46MUnavailable$1.87M

Cash flow

TuHURA Biosciences, Inc./NV cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-31
Operating cash flow-$4.41M-$5.56M-$11.09M-$6.25M-$4.74M-$2.60M-$1.89M-$5.07M-$3.83MUnavailable
Capital expenditures$48.85K$27.85K$0$5.56K$42.67K$21.41K$0UnavailableUnavailableUnavailable
Investing cash flow-$48.85K-$27.85K$0-$156.46K-$1.15M-$823.54K-$5.19MUnavailableUnavailableUnavailable
Financing cash flow$7.14M$6.51M$5.27M$8.70M-$547.88K-$3.52M$15.71M$12.95M$4.63MUnavailable
Net change in cash$2.68M$922.53K-$5.82M$2.29M-$6.44M-$6.94M-$1.89M$7.85M$796.46KUnavailable
Stock-based compensation$2.80M$2.15M$1.45M$1.41M$1.42M$1.08M$269.28K$275.49K$334.60KUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$23.47K$22.54K$21.29K$13.37K$14.06K$17.64K$29.14K$35.63K$34.31KUnavailable

Derived

TuHURA Biosciences, Inc./NV derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-31
Free cash flow-$4.46M-$5.58M-$11.09M-$6.25M-$4.78M-$2.62MUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio1.15x0.78x0.40x0.83x3.00x3.68x1.54x2.45x5.04x1.16x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open HURA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

4 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

cash flow reconciliationreview2024-09-30

Operating, investing and financing flows differ from the reported change in cash by 10513204, beyond tolerance 1000000.

balance equationreview2024-09-30

Difference 4462245 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2024-06-30

Difference 10715834 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2024-03-31

Difference 11988284 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.